Critical updates in an ever-changing environment

Novartis submitted an application to the FDA in 2Q 2025 for an intrathecal formulation (OAV101IT) of their one-time gene therapy onasemnogene abeparvovec (OAV101IT) for the treatment of spinal...

Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...

Critical updates in an ever-changing environment.

Learn with Biosimilar Basics. Part 2 covers biosimilar naming conventions and other nomenclature including common drug pipeline content acronyms.

Drug pipeline for October 2026 At Prime Therapeutics (Prime), we have positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen eye on...

Zolgensma, which was FDA approved in May 2019, is administered as an intravenous (IV) infusion, with dosing based on patient weight, in pediatric patients under 2 years of age with SMA caused by...

Editorial team The American College of Physicians (ACP) has released a clinical practice guideline on use of pharmacological treatment for prevention of episodic migraine, defined as one to 14...

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the use of GLP-1 medications to treat obesity when paired...